Renalytix (

RENX · AIM · Health Care · mcap £39m · 5.3p

Beta Briefing, track record and bull & bear case are not ready for Renalytix ( yet.

We follow 817 UK small caps and every one of their announcements – often hundreds per company. 29 companies are already wired into a briefing: browse them.

All announcements Monitoring checked today, 21:35

All · 103 Key · 28

Date	Type	Announcement	Day
05 Oct 26	Holding	Holding(s) in Company
02 Oct 26	Director dealing	Director/PDMR Shareholding (Replacement)
02 Oct 26	Holding	Holding(s) in Company
01 Oct 26	Holding	Holding(s) in Company
01 Oct 26	Director dealing	Director/PDMR Shareholding
01 Oct 26	Holding	Holding(s) in Company
30 Sep 26	Holding	Holding(s) in Company
28 Sep 26		Result of General Meeting LONDON and NEW YORK, 28 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that at the General Meeting (“GM”) held earlier today, all	+0.0%
28 Sep 26	Board change	Directorate Change Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focussed on kidney disease, announces that Julian Baines MBE has indicated his intention to stand down as Non-Executive Chair of Renalyti	+0.0%
25 Sep 26		Investor Presentations LONDON and NEW YORK, 25 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that it will host a live online investor presentation next	+0.0%
16 Sep 26	Holding	Holding(s) in Company
16 Sep 26	Holding	Holding(s) in Company
16 Sep 26	Board change	Additional CEO Share Purchase LONDON and NEW YORK, 16 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that on 11 September and 15 September 2026 James McCullough	+5.0%
14 Sep 26	Holding	Holding(s) in Company
14 Sep 26		New Accounting Ref Date Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focussed on kidney disease, announces that it has resolved to change the Company's accounting reference date.	+1.6%
11 Sep 26	Holding	Holding(s) in Company
11 Sep 26	Holding	Holding(s) in Company
11 Sep 26	Board change	CEO Share Purchase LONDON and NEW YORK, 11 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that on 8 September 2026 and 9 September 2026 James McCullo	+12.5%
10 Sep 26	Holding	Holding(s) in Company
09 Sep 26	Holding	Holding(s) in Company
09 Sep 26	Holding	Holding(s) in Company
08 Sep 26	Routine	Posting of Circular and Notice of AGM
08 Sep 26	Holding	Holding(s) in Company
08 Sep 26	Holding	Holding(s) in Company
08 Sep 26		Capital Access Window - Renalytix Plc	+30.1%
08 Sep 26	Fundraise	Result of WRAP Retail Offer Renalytix is pleased to announce, further to its announcement of 3 September 2026, the completion of the WRAP Retail Offer at an issue price of £0.06 per Ordinary Share (the "Placing Price").	+30.1%
04 Sep 26	Holding	Holding(s) in Company
03 Sep 26	Offer	WRAP Retail Offer for up to £1,000,000 Renalytix is pleased to announce a retail offer via the Winterflood Retail Access Platform ("WRAP") to raise up to £1,000,000 (the "WRAP Retail Offer") through the issue of new ordinary shares of £0.0025 each in the capi	+0.0%
03 Sep 26	Fundraise	Result of Fundraise Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focussed on kidney disease, confirms that, further to the Company's announcement released at 7.01 a.m. on 1 September 2026 (RNS Number: 8	+0.0%
02 Sep 26	Holding	Holding(s) in Company
01 Sep 26	Holding	Holding(s) in Company
01 Sep 26		Capital Access Window - Renalytix plc	+0.0%
01 Sep 26	Fundraise	Proposed Fundraise 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED ("UK MAR").	+0.0%
01 Sep 26		Collaboration with Quest Diagnostics Collaboration with Quest Diagnostics to expand kidneyintelX.dkdTM testing in the United States	+0.0%
24 Aug 26		AIM Rule 17 Disclosure LONDON and NEW YORK, 24 August 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focussed on kidney disease, provides the following update pursuant to Rule 17 and Schedule 2 (g) (v	+10.4%
10 Aug 26	Holding	Holding(s) in Company
29 Jul 26	Holding	Holding(s) in Company
27 Jul 26	Holding	Holding(s) in Company
07 Jul 26	Holding	Holding(s) in Company
30 Jun 26		Real world evidence study data published · Landmark study of 2,470 patients across two U.S. health systems demonstrates sustained risk prognosis, improvements in kidney function, increases in guideline-directed therapy uptake, and measurable reduction in indivi	+21.1%
29 May 26	Holding	Holding(s) in Company
27 May 26	Holding	Holding(s) in Company
18 May 26	Holding	Holding(s) in Company
05 May 26	Holding	Holding(s) in Company
05 May 26	Holding	Holding(s) in Company
01 May 26	Holding	Holding(s) in Company
29 Apr 26	Holding	Holding(s) in Company
23 Apr 26	Holding	Holding(s) in Company
23 Apr 26	Holding	Holding(s) in Company
22 Apr 26		Key milestones achieved for kidneyintelX.dkd Key regulatory milestones achieved in support of scaling of kidneyintelX.dkd	+0.0%
16 Apr 26	Holding	Holding(s) in Company
16 Apr 26	Holding	Holding(s) in Company
09 Apr 26	Holding	Holding(s) in Company
07 Apr 26	Holding	Holding(s) in Company
07 Apr 26	Holding	Holding(s) in Company
30 Mar 26	Holding	Holding(s) in Company
26 Mar 26	Results	Half-year Results LONDON and NEW YORK, 26 March, 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd , is the only FDA-approved and Medicare-reimbursed prognostic test	+6.8%
18 Mar 26	Holding	Holding(s) in Company
17 Mar 26	Holding	Holding(s) in Company
13 Mar 26	Holding	Holding(s) in Company
27 Feb 26	Holding	Holding(s) in Company
13 Feb 26	Board change	Further CEO Share Purchase LONDON and NEW YORK, 13 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test	+1.9%
13 Feb 26	Director dealing	Director/PDMR Shareholding
12 Feb 26	Director dealing	Director/PDMR Share Purchase LONDON and NEW YORK, 12 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test	−1.8%
12 Feb 26	Board change	CEO Share Purchase LONDON and NEW YORK, 12 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test	−1.8%
11 Feb 26	Trading update	H1 Trading update LONDON and NEW YORK, 11 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test	−26.3%
21 Jan 26	Holding	Holding(s) in Company
15 Jan 26	Holding	Holding(s) in Company
12 Jan 26		Three kidneyintelX.dkd Clinical Integrations LONDON and NEW YORK, 12 January 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support e	+0.0%
09 Jan 26	Holding	Holding(s) in Company
06 Jan 26	Holding	Holding(s) in Company
24 Dec 25	Holding	Holding(s) in Company
23 Dec 25	Holding	Holding(s) in Company
19 Dec 25	Holding	Holding(s) in Company
17 Dec 25	Holding	Holding(s) in Company
16 Dec 25	Holding	Holding(s) in Company
09 Dec 25	Routine	Result of AGM
09 Dec 25		AGM Statement LONDON and NEW YORK, 9 December 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support e	−7.4%
27 Nov 25	Holding	Holding(s) in Company
25 Nov 25	Holding	Holding(s) in Company
25 Nov 25		Plan to Implement ADS Ratio Change Renalytix Announces Plan to Implement ADS Ratio Change	+0.0%
12 Nov 25		Pivotal kidneyintelX.dkd data published Pivotal kidneyintelX.dkd data published in Diabetes Care Journal of the American Diabetes Association	−5.5%
05 Nov 25	Holding	Holding(s) in Company
04 Nov 25	Routine	Publication of Annual Report & Notice of AGM
03 Nov 25	Holding	Holding(s) in Company
03 Nov 25	Results	Audited Full Year Fiscal 2025 Results LONDON and NEW YORK, 3 November 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support e	−10.5%
30 Oct 25	Holding	Holding(s) in Company
28 Oct 25	Holding	Holding(s) in Company
27 Oct 25		Confirmation of receipt of £860k R&D tax credits Confirmation of receipt of £860k of R&D tax credits	+1.4%
24 Oct 25	Holding	Holding(s) in Company
23 Oct 25	Holding	Holding(s) in Company
21 Oct 25	Holding	Holding(s) in Company
17 Oct 25	Holding	Holding(s) in Company
17 Oct 25	Holding	Holding(s) in Company
16 Oct 25	Holding	Holding(s) in Company
16 Oct 25	Holding	Holding(s) in Company
15 Oct 25	Holding	Holding(s) in Company
10 Oct 25	Holding	Holding(s) in Company
10 Oct 25	Holding	Holding(s) in Company
10 Oct 25	Holding	Holding(s) in Company
10 Oct 25		$4m balance sheet improvement with bond conversion The conversion of the Convertible Bonds will provide a significant improvement to Renalytix's balance sheet, improving the Company's net asset position by approximately $4m and saving up to $1.4m in accrued interest over	+2.8%
09 Oct 25	Holding	Holding(s) in Company
07 Oct 25	Holding	Holding(s) in Company

Company filings. Not investment advice.